Leonard Altman, MD
Allergy & Immunology · Seattle, WANPI 1407892466
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Biocryst US Sales Co., LLC at 28.1% of the total. Reporting peaked in 2019 at $29,437 and has fallen 97.6% since, to $697 in 2025. Among allergy & immunology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 269 payments — averaging $300.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst US Sales Co., LLC$23K
- Shire North American Group Inc$18K
- Pharming Healthcare, Inc.$12K
- Cardinal Health 110 LLC$9K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- AstraZeneca$3K
- plus $7K from 17 others
What the payments were for
- Consulting fees$22,51028%
- Speaking & faculty fees$44,18055%
- Travel & lodging$3,5114%
- Food & beverage$10,55513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst US Sales Co., LLC | 46 | $22,719 |
| Shire North American Group Inc | 31 | $18,471 |
| Pharming Healthcare, Inc. | 22 | $12,382 |
| Cardinal Health 110 LLC | 13 | $9,450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $7,536 |
| AstraZeneca | 52 | $3,136 |
| Biocryst Pharmaceuticals, Inc. | 1 | $2,750 |
| Sanofi | 27 | $2,029 |
| Novartis | 14 | $285 |
| Alk-abello, Inc | 5 | $263 |
| ADMA Biomanufacturing LLC | 4 | $260 |
| Regeneron Healthcare Solutions, Inc. | 3 | $255 |
| Genentech, Inc. | 3 | $238 |
| Boehringer Ingelheim | 6 | $209 |
| GSK | 6 | $204 |
| Blueprint Medicines Corporation | 2 | $151 |
| Genentech USA, Inc. | 2 | $101 |
| Kaleo, Inc. | 3 | $74 |
| Pfizer | 3 | $69 |
| CSL Behring | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Amgen | 1 | $23 |
| Optinose US, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,755 in reported general payments places this provider in the 95th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Seattle
- Frank VirantSeattle$107K
- Daniel PetroniSeattle$68K
- Rahool DaveSeattle$42K
- Matthew AltmanSeattle$37K
- Gabriel MendozaSeattle$16K
- Kelly ColasSeattle$14K
- Jing Yi SunSeattle$11K
- Paul WilliamsSeattle$7K
- Susan XieSeattle$7K
- Matthew PerezSeattle$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.